Dova Pharmaceuticals (Dova Pharmaceuticals) Shares Outstanding (Diluted Average) : 28.80 Mil (As of Sep. 2019)

View and export this data going back to 2017. Start your Free Trial

What is Dova Pharmaceuticals Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Dova Pharmaceuticals's average diluted shares outstanding for the quarter that ended in Sep. 2019 was 28.80 Mil.

Dova Pharmaceuticals Shares Outstanding (Diluted Average) Historical Data

The historical data trend for Dova Pharmaceuticals's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dova Pharmaceuticals Shares Outstanding (Diluted Average) Chart

Dova Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Shares Outstanding (Diluted Average)

21.44

27.80

Dova Pharmaceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Shares Outstanding (Diluted Average)	Get a 7-Day Free Trial									28.20	28.21	28.22	28.29	28.80

Dova Pharmaceuticals Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

Dova Pharmaceuticals (NAS:DOVA) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

Dova Pharmaceuticals Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of Dova Pharmaceuticals's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.

Dova Pharmaceuticals (Dova Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dova Pharmaceuticals Inc (NAS:DOVA) » Definitions » Shares Outstanding (Diluted Average)

Comparable Companies

Traded in Other Exchanges

N/A

Address

240 Leigh Farm Road, Suite 245, Durham, NC, USA, 27707

Website

http://www.dova.com

Dova Pharmaceuticals Inc is a United States based clinical-stage pharmaceutical company engaged in developing treatments for patients suffering from orphan diseases. It is focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. The company's drug candidate, avatrombopag, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that it is developing for the treatment of thrombocytopenia. The company's drug candidate, avatrombopag, is designed to mimic the effects of thrombopoietin, in vitro and in vivo. Thrombopoietin is a hormone produced in the liver and kidney that binds to its receptor.

Executives

Nancy Wysenski	director	2200 SUNBURST STREET, CHATSWORTH CA 90401
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Allen Lee F Md Phd	officer: Chief Medical Officer	C/O AMAG PHARMACEUTICALS, INC., 125 CAMBRIDGEPARK DRIVE, 6TH FLOOR, CAMBRIDGE MA 02140
Roger Jeffs	director
Alfred J Novak	director	325 NE 6TH ST, BOCA RATON FL 33432
David Zaccardelli	director, officer: President & CEO	300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
Paul B Manning	director, 10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Stalfort John A Iii	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Jason Hoitt	officer: Chief Commercial Officer	C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Alex Sapir	director, officer: President & CEO	C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707